STXC SPRL
The score of STXC shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +62 % Total assets +53 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
STXC's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 179,255 € | ||||
| Equity | 199,660 € | ||||
| Cash | 159,524 € | ||||
| EBITDA | 240,669 € | ||||
| Total assets | 210,455 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 16 Jun 2026
- Year ended 31 Dec 2024filed on 24 Jun 2025
- Year ended 31 Dec 2023filed on 07 Jun 2024
- Year ended 31 Dec 2022filed on 09 Jun 2023
- Year ended 31 Dec 2021filed on 08 Jun 2022
STXC's financial analysis
- Solvency94.9%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of STXC
STXC's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0631.695.672
- VAT number
- BE0631695672
- Peppol
- Registered · 0208:0631695672 · as of 10 Nov 2026
- Legal form
- SPRL
- Incorporated
- 02 Jun 2015
- Registered office
- 9300 Aalst
- Latest accounts
- 2025 · filed on 16 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
STXC (SPRL) has been based in Aalst since 2015, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 179,255 € and equity of 199,660 €; its revenue is not published. Its solvency stands at 94.9%, above the median of its sector (60.4%).
Companies similar to STXC
Companies in the same business, of comparable size and area, outside its group.
- NanoBiotech Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 1,834 €
- TereLabs Research and experimental development on natural sciences and engineering Brussels · balance sheet 207,737 €
- GMPharm Research and experimental development on natural sciences and engineering Perwez · balance sheet 215,626 €
- Ceperitus Research and experimental development on natural sciences and engineering Ghent · balance sheet 217,514 €
- Arquebus Solutions Europe Research and experimental development on natural sciences and engineering Machelen (Brab.) · balance sheet 186,058 €
- Hephaistos-Belgium Research and experimental development on natural sciences and engineering Liège · balance sheet 242,189 €
- OCTIMET Oncology Research and experimental development on natural sciences and engineering Geel · balance sheet 252,753 €
- ImmuneWatch Research and experimental development on natural sciences and engineering Antwerp · balance sheet 173,740 €
Frequently asked questions about STXC
What is the revenue of STXC?
STXC files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of STXC?
In Belgium, the VAT number is the company number prefixed with BE: BE0631695672 for STXC, if the company is VAT-registered. Its company number (CBE) is 0631.695.672.
Where is the registered office of STXC?
According to the CBE register, the registered office of STXC is in 9300 Aalst.
What is the equity of STXC?
At the close of the 2025 financial year, the equity of STXC amounts to 199,660 €, a solvency of 94.9% of total assets.
Who manages STXC?
The register lists 1 active mandates at STXC. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of STXC
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →